Aripiprazole in tourette’s syndrome in adults: case report and narrative review
DOI:
https://doi.org/10.25118/2763-9037.2019.v9.61Keywords:
Tourette’s syndrome, aripiprazole, treatmentAbstract
Tourette’s syndrome is a movement disorder characterized by motor and vocal tics that arise in childhood and adolescence; half to two-thirds of the cases remit still in these stages. The disorder is more rarely found in adulthood, usually having a guarded prognosis and symptoms that are difficult to control in this population. This article describes the use of aripiprazole for the treatment of Tourette’s syndrome in a young male adult and conducts a narrative literature review of the evidence currently available on the use of this medication.
Downloads
Metrics
References
Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourett e syndrome – new therapeuti c opti on. Neurol Neurochir Pol. 2018;52:84-7. DOI: https://doi.org/10.1016/j.pjnns.2017.10.015
Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, et al. Randomized, double-blind, placebo-controlled trial demonstrates the effi cacy and safety of oral aripiprazole for the treatment of Tourett e’s disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27:771-81. DOI: https://doi.org/10.1089/cap.2016.0026
Gerasch S, Kanaan AS, Jakubovski E, Müller-Vahl KR. Aripiprazole improves associated comorbid conditi ons in additi on to ti cs in adult pati ents with Gilles de la Tourett e syndrome. Front Neurosci. 2016;10:416. DOI: https://doi.org/10.3389/fnins.2016.00416
Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J. Update on the role of anti psychoti cs in the treatment of Tourett e syndrome. Neuropsychiatr Dis Treat. 2012;8:95-104. DOI: https://doi.org/10.2147/NDT.S12990
Lavoie ME, O’Connor K. Toward a multi factorial concepti on of the Gilles de la Tourett e syndrome and persistent chronic ti c disorder. Brain Sci. 2017 Jun 2;7(6). pii: E61. DOI: https://doi.org/10.3390/brainsci7060061
Budman CL. The role of atypical anti psychoti cs for treatment of Tourett e’s syndrome: an overview. Drugs. 2014;74:1177-93. DOI: https://doi.org/10.1007/s40265-014-0254-0
Bhati a M, Gautam P, Kaur J. Case report on Tourett e syndrome treated successfully with aripiprazole. Shanghai Arch Psychiatry. 2014;26:297-9.
Zheng W, Li XB, Xiang YQ, Zhong BL, Chiu HF, Ungvari GS, et al. Aripiprazole for Tourett e’s syndrome: a systemati c review and meta-analysis. Hum Psychopharmacol. 2016;31:11-8. DOI: https://doi.org/10.1002/hup.2498
Wenzel C, Kleimann A, Bokemeyer S, Müller-Vahl KR. Aripiprazole for the treatment of Tourett e syndrome: a case series of 100 pati ents. J Clin Psychopharmacol. 2012;32:548-50. DOI: https://doi.org/10.1097/JCP.0b013e31825ac2cb
Taskiran S, Tufan AE, Semerci B. Aripiprazole can a viable choice for persistant suppression of symptoms in managing chronic ti c disorders and Tourett e’s disorder through the life span: a case series. Klinik Psikofarmakol Bü lteni. 2016;26:181-5. DOI: https://doi.org/10.5455/bcp.20160220032354
Yang C, Hao Z, Zhu C, Guo Q, Mu D, Zhang L. Interventi ons for ti c disorders: an overview of systemati c reviews and meta analyses. Neurosci Biobehav Rev. 2016;63:239-55. DOI: https://doi.org/10.1016/j.neubiorev.2015.12.013
Ghanizadeh A. Systemic review of aripiprazole for the treatment of children and adolescents with ti c disorders. Neurosciences (Riyadh). 2012;17:200-4.
Yang CS, Huang H, Zhang LL, Zhu CR, Guo Q. Aripiprazole for the treatment of ti c disorders in children: a systemati c review and meta-analysis. BMC Psychiatry. 2015;15:179. DOI: https://doi.org/10.1186/s12888-015-0504-z
Eddy CM, Rickards HE, Cavanna AE. Treatment strategies for ti cs in Tourett e syndrome. Ther Adv Neurol Disord. 2011;4:25-45. DOI: https://doi.org/10.1177/1756285610390261
Padala PR, Qadri SF, Madaan V. Aripiprazole for the treatment of Tourett e’s disorder. Prim Care Companion J Clin Psychiatry. 2005;7:296-9. DOI: https://doi.org/10.4088/PCC.v07n0605
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
